(±)-{(E)-4-乙基-2-[(Z)-羟亚氨基]-5-硝基-3-己烯基-1-基}-吡啶甲酰胺
![(±)-{(E)-4-乙基-2-[(Z)-羟亚氨基]-5-硝基-3-己烯基-1-基}-吡啶甲酰胺结构式](https://image.chemsrc.com/caspic/296/162626-99-5.png)
(±)-{(E)-4-乙基-2-[(Z)-羟亚氨基]-5-硝基-3-己烯基-1-基}-吡啶甲酰胺结构式
|
常用名 | (±)-{(E)-4-乙基-2-[(Z)-羟亚氨基]-5-硝基-3-己烯基-1-基}-吡啶甲酰胺 | 英文名 | nor 4 |
|---|---|---|---|---|
| CAS号 | 162626-99-5 | 分子量 | 306.31700 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C14H18N4O4 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
Eur. J. Pharmacol. 257 , 123, (1994) (+-)-(E)-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide (FK409), which was isolated from microbial products, has been reported to show a vasorelaxant effect through a mechanism similar to that of the organic nitrates such as isosorbide dinitrate. In solutio... |
期刊文献综述：
更多...